IV Omadacycline Shortens Fever in Pediatric Mycoplasma Pneumonia

Key Takeaways

• Among hospitalized children aged 8 to 16 years with macrolide-unresponsive Mycoplasma pneumoniae pneumonia, second-line intravenous omadacycline was associated with faster fever resolution than continued azithromycin.
• Defervescence within 72 hours was more common with intravenous omadacycline.
• Systemic corticosteroid use was lower in the omadacycline group.

Persistent fever after 72 hours of azithromycin can leave hospitalized children with Mycoplasma pneumoniae pneumonia in a therapeutic gray zone once macrolide therapy no longer appears to be working. When that happens, clinicians may need to choose between continuing a failing macrolide and escalating treatment without clear short-term safety data in older children. One comparison explored switching to second-line intravenous omadacycline rather than continuing azithromycin during hospitalization.

In a retrospective cohort from a pediatric center in Nanjing, China, investigators evaluated 64 children aged 8 to 16 years hospitalized with macrolide-unresponsive Mycoplasma pneumoniae pneumonia between September 2023 and December 2024. All had fever above 38.0 °C after 72 hours of azithromycin monotherapy. Eighteen children received intravenous omadacycline and 46 continued azithromycin. Omadacycline dosing used body surface area (BSA)-based scaling from the approved adult regimen, with a loading dose on day 1 followed by once-daily maintenance for 7 days. The primary outcome was time to defervescence (TTD). Secondary outcomes included 72-hour defervescence, radiological improvement, corticosteroid use, and adverse events, and the 3-month follow-up included dental examinations.

Fever cleared sooner with intravenous omadacycline, with TTD of 50.78 ± 20.71 hours versus 72.46 ± 25.61 hours with continued azithromycin (P = 0.002). Defervescence within 72 hours was also more frequent, at 55.6% versus 26.1% (P = 0.026).

Corticosteroid requirement was lower with omadacycline, at 27.8% versus 67.4% (P = 0.004). Radiological improvement did not differ significantly (P = 0.668). Adverse events occurred in 5.6% of the omadacycline group and 8.7% of the azithromycin group (P = 0.645).

This retrospective, single-center cohort can show associations rather than causal effects. Treatment was not randomized, the omadacycline group was small (n = 18), and the comparator was continued azithromycin rather than another second-line agent. The lower corticosteroid use and the absence of detected safety signals should be read in light of the small sample and the 3-month horizon. These findings support a signal of faster fever resolution in this specific setting but do not establish how omadacycline would perform against other escalation strategies, over longer follow-up, or in other populations.

The investigators concluded that second-line intravenous omadacycline was associated with faster fever resolution in this cohort and had an acceptable short-term safety profile over 3 months.

Clinician Questions

Which children with Mycoplasma pneumoniae pneumonia were represented in the IV omadacycline comparison?

The comparison applies to hospitalized children aged 8 to 16 years whose fever remained above 38.0 °C after 72 hours of azithromycin monotherapy, treated at a single center in Nanjing, China. Because the study compared switching to intravenous omadacycline with continuing azithromycin, it does not establish whether the same pattern would apply to younger children, outpatients, or other second-line comparators.

What factors were independently associated with longer time to defervescence in macrolide-unresponsive pediatric Mycoplasma pneumoniae pneumonia?

On multivariable analysis, continued macrolide therapy, positive 23S rRNA mutation status, and systemic corticosteroid use were each independently associated with longer TTD, and the full text adds lobar consolidation. The corticosteroid association may reflect confounding by indication rather than a causal effect of steroids. These are multivariable associations, not proven causes of slower recovery.

What short-term safety monitoring was reported after intravenous omadacycline in children?

Adverse event rates were similar between groups (5.6% vs 8.7%). At 3 months, no clinically significant hematologic, hepatic, renal, or cardiac enzyme changes were observed. Dental examination found no discoloration or enamel hypoplasia in any patient. With 18 omadacycline-treated children and 3 months of follow-up, the study cannot exclude uncommon or later-emerging effects.